echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > EMBO Rep: Can tea also fight AIDS? Fudan University has found that green tea extract inhibits HIV replication.

    EMBO Rep: Can tea also fight AIDS? Fudan University has found that green tea extract inhibits HIV replication.

    • Last Update: 2020-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    AIDS (AIDS) is a human immunodeficiency virus (HIV) caused by a human immunodeficiency disease, because there has been a lack of effective means of cure, the current main antiretroviral therapy (ART) to control HIV replication and infection, but this can not completely cure AIDS, once stopped, HIV virus will immediately fight back, in addition, HIV resistance problems are increasingly prominent.
    tea is one of the most popular beverages in the world, especially in China, and many studies have shown that drinking tea has many potential benefits, especially for atherosclerotic cardiovascular disease (ASCVD), which has attracted great public and researcher attention.
    January 2020, Gu Dongfeng published a research paper in the European Journal of Preventive Cardiology, which showed that drinking tea at least three times a week was associated with healthier and longer life expectancy.
    recently, a research team led by Professor Zhu Huanzhang of Fudan University's National Key Laboratory for Genetic Engineering published a research paper online in emBO Reports magazine entitled: PEBP1 suppresses HIV transcription and inducties latency by inactivating MAPK/NF-B signaling.
    study identified phosphatidyl ethanolamine binding protein 1 (PEBP1) as a new gene that induces HIV hibernation.
    more importantly, the team also found that green tea extract EGCG can induce the activation of PEBP1, which in turn induces HIV to continue to lurk by inhibiting HIV transcription and inactivated MAPK/NF-B signaling path.
    lead authors say targeted treatment of this path pathrapy may be a new option for controlling the onset of HIV in patients.
    AIDS is difficult to cure, not only because HIV is RNA virus, mutation speed is extremely fast, but also because HIV virus can be integrated and lurking in the host cell, which has become the main obstacle to the elimination of HIV virus.
    , unfortunately, we don't know much about how HIV builds an incubation period.
    view, it is critical to explore the process of establishing the incubation period of HIV and to develop targeted treatment methods to control the disease process in AIDS patients.
    the study, the researchers used a highly complex and genome-wide sgRNA library to perform genome-wide CRISPR-Cas9 knockout library screening of CD4-T cells in a latent HIV infection model.
    the rich genes, the team found that the PEBP1 gene inhibits HIV replication and promotes the establishment of an HIV incubation period.
    Whole Genome CRISPR screening strategy PEBP1, also known as Raf kinase inhibitor protein (RKIP), which binds to Raf-1 to inhibit mapK signal transductivity and participates in the regulation of G protein-coupled binding bindular sensor pathlines and NF-B signal path paths, playing an important role in the physiological processes of membrane biosynthesis, neurodevelopment and apoptosis.
    further studies have shown that when the PEBP1 gene is removed, the Raf1/ERK/I-B and IKK/I-B/NF-B signaling paths are activated, which in turn leads to the recovery of HIV during the incubation period.
    results were validated in several HIV incubation models, including the original CD4 plus T cell model of the HIV incubation period.
    Xinyi, lead author of the paper that PEBP1 inhibits the reactivation of HIV-1 by inactivated Raf1/IKK/NF-B signal path, said PEBP1 can directly inhibit HIV-1. 1 infection, and induced HIV into the incubation period in the original CD4 plus T cells, and more importantly, the study found that PEBP1 could be activated by a small molecular substance, EGCG, extracted from Chinese's regularly drinked green tea.
    "EGCG induced PEBP1 inhibits the reactivation of HIV during the incubation period EGCG (Epigallocatechin gallate), i.e., table-free catechin no cannibalate, is the main component of green tea polyphenols, studies have shown that EGCG has antibacterial, antiviral, antioxidant, anti-atherosclerosis, anti-thrombosis, anti-vascular hyperpluration, anti-inflammatory and anti-tumor effects.
    researchers also found that when PEBP1 is induced to activate by EGCG, it inhibits nuclear-positioned NF-B, which in turn inhibits the reactivation of the latent-stage HIV virus, which is isolated from the primary CD4-T cells of HIV-positive patients who have received antiretroviral therapy.
    PEBP1 plays an important role in the establishment of HIV incubation period In summary, the above research facts show that PEBP1 plays a key role in controlling HIV transcription and incubation period establishment, and this study provides new insights into the establishment mechanism of human cognition of HIV incubation period.
    same time, Professor Zhu Huanzhang also said that their research shows that green tea extract EGCG may be a new option for future treatment of AIDS patients in the incubation period! Special Note: Biological World Public only truthfully reported how to interpret the latest research papers, does not constitute health care or medical guidance, everything is too late, tea is not a hundred and no harm, should be based on their own circumstances, reasonable and moderate tea.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.